Publication:
Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)

Simple item page
dc.contributor.authorYuste Pérez, María Teresa
dc.contributor.authorSainz Gil, María
dc.contributor.authorEscudero, Elisa
dc.contributor.authorMarín, Pedro
dc.contributor.departmentFarmacología
dc.date.accessioned2025-02-11T11:35:59Z
dc.date.available2025-02-11T11:35:59Z
dc.date.issued2025-02-07
dc.description© 2025 The authors This document is the published version of a published work that appeared in final form in Pharmacology Research & Perspectives. . This document is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0 To access the final edited and published work see: https://doi.org/10.1002/prp2.70075
dc.description.abstractAromatase inhibitors are used for patients with hormone-receptor positive breast cancer. Alzheimer's disease is the most prevalent cause of dementia. Several studies have suggested an association between the use of aromatase inhibitors and the development of Alzheimer's disease. The objective of this study was to identify potential pharmacovigilance signals associated with dementia and Alzheimer's disease and third-generation aromatase inhibitors in menopausal and postmenopausal women. VigiBase, the global database of individual case safety reports of the World Health Organization, was used to investigate this possible association. A disproportionality analysis was performed for women aged 45 years and older. The reporting odds ratio (ROR) and its 95% CI for reporting dementia are exemestane, 2.08 (1.35–3.19); anastrozole, 1.59 (1.09–2.32); and letrozole, 1.43 (1.05–1.95) and for Alzheimer's disease are exemestane, 0.94 (0.30–2.92); anastrozole: 2.63 (1.55–4.45); and letrozole, 1.33 (0.76–2.35). For senile dementia, only letrozole has cases, with an ROR of 6.77 (2.51–18.31). Signals of disproportionate reporting have been observed between the occurrence of dementia, dementia Alzheimer's type, and senile dementia with aromatase inhibitors, which is in line with estrogen functions and aromatase activity, as well as the findings from preclinical studies. Additional research is required to elucidate this intricate matter.es
dc.formatapplication/pdfes
dc.format.extent6es
dc.identifier.citationPharmacology Research & Perspectives, Volume 13, Issue 1 e70075
dc.identifier.doihttps://doi.org/10.1002/prp2.70075
dc.identifier.urihttp://hdl.handle.net/10201/150251
dc.languageenges
dc.publisherWiley; British Pharmacological Society; American Society for Pharmacology and Experimental Therapeutics (ASPET)
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.70075
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAlzheimer's diseasees
dc.subjectAnastrozolees
dc.subjectAromatase inhibitorses
dc.subjectDementiaes
dc.subjectDisproportionality analysises
dc.subjectExemestanees
dc.subjectLetrozolees
dc.subjectPharmacovigilancees
dc.titleDementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)es
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pharmacology Res Perspec - 2025 - Yuste - Dementia and Alzheimer s Disease Associated With Aromatase Inhibitors A.pdf
Size:
170.35 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos